The Opportunity

Highly contagious viruses like Influenza A and B, and SARS-CoV-2, are significant causes of morbidity and mortality. Most treatments for flu and COVID-19 – and the secondary infections that typically lead to hospitalization and can even cause death – focus on the virus. Respana is different. We’re focused on altering the patient’s inflammatory immune response to the virus, not the virus itself.


With a seasoned management team with over 100 years experience in the life sciences, Respana is currently seeking strategic partners to accelerate commercialization.

Read more

Our Technology

Respana’s proprietary therapeutic mAb (RT-002) addresses inflammatory conditions associated with respiratory diseases, including influenza and COVID-19.

Read more

Virtual Pitch

Respana has been selected as a semifinalist for the 2020 North America Advance Biotech Grant program. View our pitch to see how we are pioneering biotherapeutic development to support human health.

View video

About Us

Respana Therapeutics, Inc., is an early stage company developing therapeutics that modulate the immune response to lung disease caused by viral infection.

Tim Pelura

President & CEO

Andy Agrawal

Vice President

Michele Washko


We have over 100 years of life science industry experience

Respana in the News

Catch the latest news and updates from the members of the Respana team.

Back To Top